Technology disruption from long-read sequencing platforms (PacBio HiFi, Oxford Nanopore) that address Illumina's short-read limitations in structural variant detection and de novo assembly applications, potentially eroding market share in research segments
Regulatory expansion of FDA oversight over laboratory-developed tests (LDTs) could increase compliance costs and slow clinical diagnostics adoption, particularly affecting GRAIL integration and multi-cancer screening commercialization
Reimbursement pressure as payers scrutinize genomic testing costs, potentially limiting clinical test volumes and forcing price concessions that compress consumable margins
Market share erosion to emerging sequencing technologies offering differentiated capabilities (long-read, real-time sequencing) at improving cost-performance ratios, particularly in research applications where Illumina's short-read dominance is most vulnerable
Chinese sequencing companies (MGI/BGI) gaining traction in Asia-Pacific markets through aggressive pricing (30-50% below Illumina) and government support, threatening international expansion and creating pricing pressure in competitive geographies
GRAIL divestiture aftermath and potential litigation costs following forced separation of the multi-cancer early detection subsidiary, creating ongoing legal expenses and strategic uncertainty in clinical diagnostics
Elevated inventory levels (estimated $800M-1B) relative to current demand, risking obsolescence charges if NovaSeq X adoption cannibalizes legacy platform consumables faster than anticipated
Pension and post-retirement obligations common to mature healthcare technology companies, though not explicitly disclosed in provided fundamentals
StructuralCompetitiveBalance Sheet